Lataa...

Gastrointestinal tolerability with ibandronate after previous weekly bisphosphonate treatment

Data from two open-label trials (PRIOR and CURRENT) of women with postmenopausal osteoporosis or osteopenia were evaluated to assess whether monthly oral and quarterly intravenous (IV) ibandronate dosing improved self-reported gastrointestinal (GI) tolerability for patients who had previously experi...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Derman, Richard, Kohles, Joseph D, Babbitt, Ann
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Dove Medical Press 2009
Aiheet:
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC2762360/
https://ncbi.nlm.nih.gov/pubmed/19851511
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!